efavirenz has been researched along with Amyloid Deposits in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arakawa, H; Constans, J; Landreth, G; Li, Y; Mast, N; Maxfield, E; Pikuleva, IA; Saadane, A; Valencia-Olvera, A | 1 |
| Lam, M; Li, Y; Mast, N; Maxfield, E; Moon, J; Petrov, AM; Pikuleva, IA | 1 |
2 other study(ies) available for efavirenz and Amyloid Deposits
| Article | Year |
|---|---|
Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.
Topics: Administration, Oral; Alkynes; Alzheimer Disease; Animals; Benzoxazines; Brain; Cholesterol; Cholesterol 24-Hydroxylase; Cyclopropanes; Disease Models, Animal; Female; Learning; Liver X Receptors; Male; Memory; Mice, Transgenic; Microglia; Neuroprotective Agents; Plaque, Amyloid; Transcriptome | 2017 |
CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice.
Topics: Alkynes; Alzheimer Disease; Animals; Benzoxazines; Brain; Cholesterol 24-Hydroxylase; Conditioning, Classical; Cyclopropanes; Disease Models, Animal; Enzyme Activation; Female; Male; Maze Learning; Mice; Nootropic Agents; Plaque, Amyloid | 2019 |